Distinct plasma proteomic trajectories during PD-1 blockade and PEG-IFNα therapy are associated with HBsAg response in chronic hepatitis B
Open Access
- 10 November 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1996565
Abstract
Background: PD-1 blockade and pegylated interferon-α (PEG-IFNα) are promising immunomodulatory strategies for chronic hepatitis B (CHB), but their systemic immune effects and response-associated proteomic patterns remain poorly defined. Methods: We performed longitudinal plasma proteomic profiling using the Olink Target 96 Inflammation panel in 25 nucleos(t)ide analogue-suppressed patients with CHB receiving PD-1 blockade (n=10) or PEG-IFNα (n=15). Plasma samples were collected at baseline, week 12, and week 24. Longitudinal protein changes were analyzed using linear mixed-effects models, and associations with week-24 HBsAg decline were evaluated using responder–non-responder comparisons and Spearman’s rank correlation. Responders were defined by an HBsAg decline of ≥1 log 10 IU/mL at week 24. Results: Seventy-seven proteins passed quality-control criteria. PEG-IFNα induced substantially broader longitudinal proteomic remodeling than PD-1 blockade, with most changes occurring within the first 12 weeks. Treatment-by-time analyses identified distinct trajectories between therapies, including differential changes in IL-18R1, TNF, CX3CL1, CXCL9, and CXCL10. Response-associated analyses suggested treatment-specific patterns: IL-10 was the leading exploratory signal in the PD-1 cohort, whereas IL-12B, CDCP1, and FGF-21 were more prominent in the PEG-IFNα cohort. These response-related associations did not remain significant after false discovery rate correction and were therefore considered exploratory. Conclusions: PD-1 blockade and PEG-IFNα induce distinct longitudinal circulating inflammatory proteomic programs in CHB. Favorable HBsAg decline was accompanied by treatment-specific rather than universal proteomic signatures, supporting the potential value of longitudinal proteomics for mechanistic and biomarker studies of HBV functional-cure strategies.Keywords
Funding Information
- National Science and Technology Major Project
- National Key Research and Development Program of China
This publication has 36 references indexed in Scilit:
- Phase-specific polarization of peripheral helper T cells influences immunopathology and viral control in HBV infectionHepatology International, 2026
- Serum IP-10 increase correlated with PEG-IFNα response in nucleot(s)ide analogs-treated patients with chronic hepatitis BiLIVER, 2024
- FGF21-mediated autophagy: Remodeling the homeostasis in response to stress in liver diseasesGenes & Diseases, 2024
- Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacyAntiviral Research, 2023
- Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2021
- Autocrine IL‐10 promotes human B‐cell differentiation into IgM‐ or IgG‐secreting plasmablastsEuropean Journal of Immunology, 2014
- Response-Guided Peginterferon Therapy in Hepatitis B E Antigen-Positive Chronic Hepatitis B Using Serum Hepatitis B Surface Antigen LevelsHepatology, 2013
- Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis BJournal of Hepatology, 2013
- CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liverJournal of Hepatology, 2012
- Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or CHepatology, 2011